People with diabetes who need to track both glucose and ketone levels have long juggled separate devices, pricking their ...

Summary: Investigators demonstrated that an experimental compound called BA-101 can successfully strip away glioblastoma’s defensive armor. By selectively blocking an enzyme that fuels the tumor’s ...

Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than ten million ...

MAIA recently announced that it has completed international enrollment in Part C of the Phase 2 THIO-101 expansion trial. Treatment with ateganosine followed by cemiplimab has shown an acceptable ...

Polypharmacy in patients with cardiovascular disease occurs frequently across the age spectrum and can lead to inappropriate ...

Sino Biopharmaceutical has struck a licensing deal with AstraZeneca for a chronic respiratory disease treatment and obtained commercialization rights for two GSK treatments in China, as global ...

AstraZeneca struck a licensing deal for a chronic respiratory disease treatment with Sino Biopharmaceutical that could be valued at up to $1.9 billion, sending shares in the Chinese drugmaker sharply ...

For decades, the management of diabetic retinopathy (DR) has consisted mainly of optimizing metabolic control (blood glucose, pressure and lipids) and routine surveillance as preventive strategies, ...

Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than 10 million people ...

Researchers have identified 15-PGDH enzyme inhibition as a neuroprotective strategy in Parkinson's disease, with repurposable ...

Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than ten million ...